GlassScriptPhysician profile
Kevin Patrick Meyers
NPI 1750589610
$3,702.46
in general payments reported to CMS, 2019-2025
24 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $28.85 · 2021: $95.67 · 2022: $511 · 2023: $1,241 · 2024: $655 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,542.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $761.71 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $327.65 | 2023-2025 | Ibsrela |
| Olympus America INC. | $182.71 | 2019 | |
| Romark Laboratories, Lc | $113.61 | 2019 | |
| Braintree Laboratories, INC. | $98.50 | 2022-2024 | Suflave, Sutab |
| Boston Scientific Corporation | $93.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.01 | 2021-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $73.38 | 2024-2025 | Dupixent |
| Genzyme Corporation | $64.57 | 2023-2025 | |
| Pfizer INC. | $54.71 | 2024 | |
| Ferring Pharmaceuticals INC. | $52.89 | 2022-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $42.94 | 2019-2024 | Dificid |
| Celltrion USA INC. | $40.87 | 2025 | Vegzelma |
| Ucb, INC. | $24.79 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.74 | 2025 | Wegovy |
| Gilead Sciences, INC. | $19.23 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.96 | 2025 | Voquezna |
| Evoke Pharma, INC. | $15.90 | 2023 | Gimoti |
| Daiichi Sankyo INC. | $15.59 | 2020 | |
| Amgen INC. | $14.93 | 2023 | Amjevita, Avsola |
| Lilly USA, LLC | $14.59 | 2024 | Omvoh |
| Allergan, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.